NASDAQ:GNPX

Genprex Q3 2026 Earnings Results & Report

Genprex logo
$1.45 -0.22 (-13.17%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$1.48 +0.03 (+1.72%)
As of 11/20/2026 06:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Genprex beat analyst earnings expectations in its Q3 2026 results, released November 13, 2026. The company reported EPS of -$5.30 versus the -$6,160.00 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Time
After Market Closes

Genprex EPS Results

Actual EPS
-$5.30
Consensus EPS
-$6,160.00
Beat/Miss
Beat by +$6,154.70
One Year Ago EPS
N/A

Genprex Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Genprex's next earnings date is estimated for Wednesday, December 2, 2026, based on past reporting schedules.

Conference Call Resources

Genprex Q3 2026 Earnings FAQ

Genprex (NASDAQ:GNPX) reported earnings of -$5.30 per share for Q3 2026, beating the consensus estimate of -$6,160.00. The report was announced on Friday, November 13, 2026.

Genprex's next earnings date is estimated for Wednesday, December 2, 2026. MarketBeat tracks confirmed and estimated earnings dates for Genprex on the company's earnings history page.

Genprex Earnings Headlines

CFA: Bank of America Said THIS
On January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.tc pixel
See More Genprex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Genprex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genprex and other key companies, straight to your email.

About Genprex

Genprex (NASDAQ:GNPX), Inc. is a clinical-stage gene therapy company developing treatments for cancer and diabetes. The company is based in Austin, Texas, and its work focuses on using genetic material to address diseases with significant unmet medical needs.

Its lead cancer candidate, REQORSA (quaratusugene ozeplasmid), is an investigational, non-viral gene therapy designed to deliver the TUSC2 tumor-suppressor gene to cancer cells. Genprex has studied REQORSA in clinical trials for non-small cell lung cancer, including in combination with other cancer therapies.

Genprex is also developing an investigational gene therapy program for diabetes. Its candidates remain in development, and the company’s therapies are not approved for commercial use.

View Genprex Profile